Business Context and Reporting Period
This Form 8-K is filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on May 6, 2022, with the report date of May 11, 2022. The filing primarily addresses corporate governance changes and references the release of financial results for the quarter ended March 31, 2022.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing financial results for the three months ended March 31, 2022. However, the text of this 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Corporate Governance
Significant leadership transitions were announced effective May 6, 2022, and June 1, 2022:
- Board of Directors: Cavan Redmond stepped down as Chairman and will not stand for reelection at the 2022 Annual Meeting. He will remain a director until the meeting and serve as a trusted advisor. Andrew Arno was appointed Chairman effective May 6, 2022.
- Chief Financial Officer: Mitchell Levine ceased serving as CFO on June 1, 2022, transitioning to the role of Corporate Development Officer.
- Interim CFO Appointment: Anish John, previously VP of Operations – Transplant, was appointed Senior Vice President, Finance, and Interim Chief Financial Officer effective June 1, 2022.
Compensation and Equity Grants
As part of his appointment, Anish John received the following compensation package:
- Base Salary: $275,000 annually.
- Target Bonus: 40% of annual base salary, discretionary based on performance goals.
- Equity Grant: 50,000 stock options under the 2018 Equity Incentive Plan.
- Vesting Schedule: 25% vests after one year of continuous service; the remaining 75% vests in 36 equal monthly installments thereafter.
- Option Terms: Exercise price set at fair market value on the grant date; 10-year expiration.
Outlook, Risks, and Forward-Looking Statements
The filing includes standard forward-looking statements regarding future performance, noting that actual results may differ due to risks detailed in the Company's Form 10-K. The text explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" under the Exchange Act, limiting its incorporation by reference into other filings.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended March 31, 2022, by reviewing the attached press release (Exhibit 99.1), as this 8-K does not contain the data.
- Confirm the effective dates of the CFO transition (June 1, 2022) and the new Chairman appointment (May 6, 2022).
- Review the vesting terms of the 50,000 stock options granted to the new Interim CFO.
- Note that Cavan Redmond remains a director until the 2022 Annual Meeting despite stepping down as Chairman.